Innate Pharma (IPHA) Receivables - Net (2017 - 2025)

Innate Pharma (IPHA) has reported Receivables - Net for 9 consecutive years, with $14.4 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Net fell 11.53% year-over-year to $14.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.4 million (down 11.53% YoY) and the FY2025 annual result came in at $14.4 million, down 11.53% from the prior year.
• Receivables - Net retreated to $14.4 million in Q4 2025 per IPHA's latest filing, from $19.3 million in the prior quarter.
• Over the last five years, Receivables - Net for IPHA reached as high as $70.0 million in Q2 2022 and fell as low as $14.4 million in Q4 2025.
• A 5-year average of $41.8 million and a median of $45.2 million in 2021 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2021 — Receivables - Net plunged 99.68% — and 2022, when it jumped 184.72%.
• Year by year, Receivables - Net stood at $21.0 million in 2021, then jumped by 184.72% to $59.7 million in 2022, then grew by 5.93% to $63.2 million in 2023, then plunged by 74.26% to $16.3 million in 2024, then decreased by 11.53% to $14.4 million in 2025.
• According to Business Quant data, Receivables - Net over the past three periods registered $14.4 million, $19.3 million, and $16.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.